Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00604)
Name	Roflumilast
Synonyms	Click to Show/Hide the Synonyms of This API Roflumilast; 162401-32-3; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; Daliresp; BYK20869; UNII-0P6C6ZOP5U; B9302-107; BY 217; BY-217; Roflumilast (Daxas); Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; 0P6C6ZOP5U; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; CHEMBL193240; CHEBI:47657; Roflumilast-d3; BYK-20869; B 9302-107; Libertek; Roflumilast [USAN:INN]; roflumilastum; C17H14Cl2F2N2O3; Roflumilast (JAN/USAN/INN); APTA-2217; Daliresp (TN); BYK 20869; 1189992-00-4; 3-Cyclopropylmethoxy-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide; SCHEMBL19158; cc-305; MLS006010074; ARQ-151 (roflumilast cream); BEN530; GTPL6962; DTXSID8044123; BDBM14774; Roflumilast, >=98% (HPLC); EX-A059; HMS3655P21; HMS3748C19; HMS3884F09; ZINC592419; ACT02619; BCP03736; EBD15341; CR0025; MFCD00938270; AKOS005146309; AM84550; CCG-268678; CS-0963; DB01656; PB29130; QC-1593; NCGC00346566-01; NCGC00346566-09; AC-23383; AK110425; AS-14120; HY-15455; SMR002530074; BCP0726000146; AB0031354; FT-0660846; SW220196-1; A10804; A24672; D05744; Q-4353; AB01565852_02; 401R323; Q693482; J-510858; BRD-K03194791-001-02-2; B-9302-107; 3- cyclo-propylmethoxy-4-difluoromethoxy-N- [3, 5-di-chloropyrid-4-yl]- benzamid; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; n-(3,5-dichloropyridin-4-yl)-4-difluoromethoxy-3-cyclopropylmethoxybenzamide
Clinical Status	Approved
Disease Indication	Chronic obstructive pulmonary disease		ICD-11: CA22	[1]
PubChem CID	449193
Formula	C17H14Cl2F2N2O3
Canonical SMILES	C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
InChI	1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
InChIKey	MNDBXUUTURYVHR-UHFFFAOYSA-N
	Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure	<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=449193"></iframe>
Structure	3D MOL		2D MOL
Physicochemical Properties	Molecular Weight	403.2	Topological Polar Surface Area	60.4
	XlogP	4.6	Complexity	475
	Heavy Atom Count	26	Rotatable Bond Count	7
	Hydrogen Bond Donor Count	1	Hydrogen Bond Acceptor Count	6

Full List of Drug Formulations (DFMs) Containing This API
Roflumilast 0.5 mg tablet			Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s)
Drug Formulation 1	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Lactose monohydrate; Magnesium stearate; Povidone; Starch, corn
Dosage Form	Oral Tablet
Company	Forest Laboratories
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Povidone	DIG Info	Cholesterol 25-hydroxylase (IC50 = 78.3 uM)	[2]
	Magnesium stearate	DIG Info	Albendazole monooxygenase (Protein expression downregulation)	[3]
Drug Formulation 2	DFM Info click to show the detail info of this DFM
All DIGs	Click to Show/Hide the Full List of DIGs in This DFM Lactose monohydrate; Magnesium stearate; Povidones; Starch, corn
Dosage Form	Oral Tablet
Company	AstraZeneca; Cardinal Health
DIG(s) with Biological Activity
	DIG Name	DIG Info	Representative Biological Activity of This DIG	REF
	Magnesium stearate	DIG Info	Albendazole monooxygenase (Protein expression downregulation)	[3]

References
1	FDA label for approved roflumilast from the official website of the U.S. Food and Drug Administration.
2	Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
3	Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.